PARP inhibitor

PathAI Present Machine Learning Models that Predict the Homologous Recombination Deficiency Status of Breast Cancer Biopsies at the 2020 SABCS

Retrieved on: 
Wednesday, December 9, 2020
Branches of biology, DNA repair, Biology, Poly (ADP-ribose) polymerase, Programmed cell death, PARP, Biopsy, Breast cancer, Homologous recombination, Cancer, HRDetect, PARP inhibitor

DNA damage repair pathways, such as homologous recombination, have essential roles in healthy cells, and mutations in these pathways are closely associated with an increased risk for cancer, as well as cancer progression.

Key Points: 
  • DNA damage repair pathways, such as homologous recombination, have essential roles in healthy cells, and mutations in these pathways are closely associated with an increased risk for cancer, as well as cancer progression.
  • HRD tumors are sensitive to poly-ADP ribose polymerase (PARP) inhibitors and platinum-based chemotherapy, making determination of a patient's tumor HRD status clinically important.
  • PathAI used two different approaches to predict the HRD status of a tumor from the H&E-stained tissue biopsy.
  • Models were trained using breast cancer tumor biopsy images from TCGA and HRD scores of these same biopsies generated by Knijnenburg and colleagues (published in Cell Reports.

Up-and-coming Canadians recognized for breakthroughs in medicine, computing, environment, COVID-19 protection, and more

Retrieved on: 
Tuesday, November 24, 2020
Companies, Health, Sanofi, PARP inhibitor, Sanofi Pasteur, Ciena, Saab Automobile, Virus

They include six awards for outstanding innovation, one for exceptional leadership, and one for commercialization of a novel idea.

Key Points: 
  • They include six awards for outstanding innovation, one for exceptional leadership, and one for commercialization of a novel idea.
  • The 2020 Mitacs Awards event partners and sponsors include: Ciena, Platinum Partner; NRC-IRAP, Event Supporter; The Hill Times, Media Partner; Sanofi Pasteur, Gold Sponsor; and Saab, Silver Sponsor.
  • The goal is to provide mini sanitization units to long-term care homes, day cares, hospitals, airports, retail businesses, schools, and households.
  • The viruses have been shown to overcome resistance to PARP inhibitors, a cancer therapy to which patients often develop resistance.

Onxeo Receives Notice of Intent to Grant a New Patent Enhancing the Protection in Europe of AsiDNA™ Combined with PARP Inhibitors

Retrieved on: 
Thursday, October 22, 2020
Branches of biology, Biology, Cellular processes, PARP inhibitor, Homologous recombination, DNA repair, SiDNA, MRN complex, PARP1

It completes the already robust set of patent families protecting AsiDNA and its related compounds, alone or in combination.

Key Points: 
  • It completes the already robust set of patent families protecting AsiDNA and its related compounds, alone or in combination.
  • The granted patent is based on the fact that AsiDNA is able, through its original mechanism of action, to block all DNA repair pathways, including the homologous recombination pathway.
  • Now, another complementary application of AsiDNA appears, in combination with PARP inhibitors in HR-proficient patients with little or no sensitivity to PARPi alone.
  • AsiDNA has also shown a strong synergy with other tumor DNA-damaging agents such as chemotherapy and PARP inhibitors.

Onxeo Receives Notice of Allowance from USPTO for New Patent Strengthening Protection of AsiDNA™ via Systemic Administration in the United States

Retrieved on: 
Thursday, September 3, 2020
Clinical medicine, Antineoplastic drugs, Cancer treatments, PARP inhibitor, Health, SiDNA, DNA, Chemotherapy, Articles

The new U.S. patent will add to the robust patent portfolio built around AsiDNA, the Companys first-in-class DNA Damage Response (DDR) inhibitor.

Key Points: 
  • The new U.S. patent will add to the robust patent portfolio built around AsiDNA, the Companys first-in-class DNA Damage Response (DDR) inhibitor.
  • Building a strong intellectual property protection around our assets is a key element of our value creation strategy and of course makes sense for AsiDNA, the most advanced first-in-class asset in our portfolio.
  • This new patent adds a complementary line of protection until 2037 for the use of AsiDNA in two indications with high medical need and for which AsiDNA in combination with a "DNA-breaker" treatment could represent a major therapeutic response.
  • AsiDNA has also shown a strong synergy with other tumor DNA-damaging agents such as chemotherapy and PARP inhibitors.

Rain Therapeutics Announces License Agreement for the Development of Proprietary RAD52 Inhibitors in the DNA Damage Response Pathway

Retrieved on: 
Tuesday, August 25, 2020
Branches of biology, Biology, DNA repair, RAD52, Homologous recombination, PARP inhibitor, BRCA1, Synthetic lethality

RAD52 is a novel and rational oncology target, and weve been very impressed with the advances in the field made by Drexel researchers.

Key Points: 
  • RAD52 is a novel and rational oncology target, and weve been very impressed with the advances in the field made by Drexel researchers.
  • RAD52 is involved in several DDR pathways, and RAD52 inactivation is synthetically lethal in cancer cells with BRCA1/2 and other homologous recombination (HR) gene mutations.
  • Drexels RAD52-targeted inhibitors have evidenced potent in vitro and in vivo activity in BRCA1-deficient xenograft models, alone and in combination with PARP inhibitors.
  • Drexel University will also receive milestone payments and royalties based on successful development and commercialization of proprietary programs.

BeiGene Announces Acceptance of a New Drug Application of Pamiparib in Ovarian Cancer in China

Retrieved on: 
Friday, July 17, 2020
RTT, Cancer, Health, Medicine, Gynaecological cancer, Gynaecology, Ovarian cancer, Oncology, Triple-negative breast cancer, Breast cancer, Cofetuzumab pelidotin, PARP inhibitor

For patients in China with advanced ovarian cancer, we are hopeful that pamiparib can offer a new treatment option.

Key Points: 
  • For patients in China with advanced ovarian cancer, we are hopeful that pamiparib can offer a new treatment option.
  • This NDA is supported by clinical results from a Phase 1/2 trial of pamiparib in patients with advanced ovarian cancer, fallopian cancer, and primary peritoneal cancer or advanced triple negative breast cancer (NCT03333915).
  • A new drug applications (NDA) for pamiparib for patients with ovarian cancer has been accepted by the Center for Drug Evaluation (CDE) of the NMPA.
  • We currently market two internally-discovered oncology products: BTK inhibitor BRUKINSA (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China.

Onxeo Confirms in Preclinical Studies the Profile of OX401, a Potent PARP Agonist with Strong Anti-Tumor Activity and Immunological Properties

Retrieved on: 
Thursday, June 25, 2020
Branches of biology, Cell biology, DNA, Biology, PARP1, cGAS–STING cytosolic DNA sensing pathway, Biomarker, Treatment of cancer, PARP inhibitor

OX401 is a potent PARP1 agonist and represents a new generation of molecules showing strong anti-tumor activity associated with high immunological activity.

Key Points: 
  • OX401 is a potent PARP1 agonist and represents a new generation of molecules showing strong anti-tumor activity associated with high immunological activity.
  • OX401 exhibits potent antitumor activity, demonstrated in an animal model of breast cancer, related to PARP hyperactivation and diversion of its DNA repair function in specific tumor cells.
  • In addition, this activity on PARP induces a strong engagement of the cGAS-STING pathway2, as shown by the increase in key biomarkers of the tumor immune response.
  • Finally, like AsiDNA, OX401 has no activity on healthy cells, which should provide a favorable safety profile in the clinic.

Tempus Launches New Precision Medicine-Driven Tests: Tempus|HRD and Tempus|TO

Retrieved on: 
Sunday, May 31, 2020
Branches of biology, Biology, Life sciences, Biotechnology, Molecular biology, Systems biology, Gene expression, RNA, PARP inhibitor, Precision medicine, DNA sequencing, Tempus

Tempus|HRD is a DNA-based test, available as a supplementary option to xT, the companys signature broad-panel genomic sequencing test that measures 648 genes, along with the full transcriptome.

Key Points: 
  • Tempus|HRD is a DNA-based test, available as a supplementary option to xT, the companys signature broad-panel genomic sequencing test that measures 648 genes, along with the full transcriptome.
  • A patients HRD status has been shown to identify whether or not they are a good candidate for PARP inhibitors and platinum-based chemotherapy.
  • Tempus|HRD is launching this week in limited markets for all cancer types, with a broad launch slated for July.
  • Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare.

Clinical Response and Translational Data from DeCidE1, a Phase 2 Study of DPX-Survivac Immunotherapy in Patients with Advanced Recurrent Ovarian Cancer

Retrieved on: 
Friday, May 29, 2020
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Cancer, Gynaecological cancer, Medicine, Gynaecology, Oncology, Ovarian cancer, RTT, Clinical medicine, PARP inhibitor, Triciribine

With these results, DPX-Survivac continues to exhibit significant and durable anti-tumor activity, paving the way for targeted T cell therapies in advanced recurrent ovarian cancer and other solid tumors.

Key Points: 
  • With these results, DPX-Survivac continues to exhibit significant and durable anti-tumor activity, paving the way for targeted T cell therapies in advanced recurrent ovarian cancer and other solid tumors.
  • We believe these results highlight DPX-Survivacs potential to alter the treatment landscape in advanced ovarian cancer and support its continued development.
  • As of data cut-off date, May 2, 2020, 19 patients were evaluable for efficacy with four patients (21%) still receiving treatment.
  • This Phase 2 arm enrolled 19 evaluable patients with recurrent, advanced platinum-sensitive and resistant ovarian cancer.

Onxeo Announces Approval of the REVocan Study by Regulatory Authorities

Retrieved on: 
Friday, May 29, 2020
PARP inhibitor

From a regulatory standpoint, the study can now be initiated.

Key Points: 
  • From a regulatory standpoint, the study can now be initiated.
  • In preclinical studies that replicated the conditions of the REVocan study3, AsiDNA demonstrated its ability to halt the acquired resistance of tumors to PARP inhibitors (class effect).
  • REVocan is therefore particularly important as it would provide proof-of-concept of the tolerability of such a combination and AsiDNA's ability to reverse resistance to this major therapeutic class.
  • Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.